Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Q3 2025 value amounting to $922848.0.

  • Orchestra BioMed Holdings' Gains from Sales and Divestitures rose 53830.9% to $922848.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $922848.0, marking a year-over-year increase of 53830.9%. This contributed to the annual value of $416368.0 for FY2024, which is 41537.07% up from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Gains from Sales and Divestitures is $922848.0, which was up 53830.9% from $625414.0 recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Gains from Sales and Divestitures registered a high of $922848.0 during Q3 2025, and its lowest value of $13100.0 during Q1 2024.
  • In the last 3 years, Orchestra BioMed Holdings' Gains from Sales and Divestitures had a median value of $112683.5 in 2023 and averaged $253482.5.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Gains from Sales and Divestitures crashed by 6485.16% in 2024 and then soared by 270429.56% in 2025.
  • Orchestra BioMed Holdings' Gains from Sales and Divestitures (Quarter) stood at $80790.0 in 2023, then soared by 415.37% to $416368.0 in 2024, then surged by 121.64% to $922848.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $922848.0 for Q3 2025, versus $625414.0 for Q2 2025 and $178286.0 for Q1 2025.